ESTEVE Expands Its Reach with Regis Technologies Acquisition
This acquisition enables ESTEVE to broaden its contract development and manufacturing services, focusing on small-molecule active pharmaceutical ingredients (APIs) from pre-clinical to commercial stages within the United States.
Acquired recently, Regis Technologies operates as a Contract Development and Manufacturing Organization (CDMO) based in Chicago. This strategic move positions ESTEVE CDMO, which functions under the Esteve Química brand, directly within the U.S. market, significantly extending its capabilities.
For over six decades, Regis Technologies has established itself in the U.S. as a reliable API CDMO, offering a variety of services that include process research and development, analytical and stability services, cGMP API manufacturing, and CMC support. Their broad service offering is complemented by high-quality chromatography products.
Joan Petit, Chief Industrial Operations Officer of ESTEVE and General Manager of Esteve CDMO, expressed pride in this acquisition stating, "We are expanding our team and enhancing our CDMO solutions for pharmaceutical innovators. This move increases our development and manufacturing capacity with the addition of around 70 skilled professionals."
Strategic Importance of This Acquisition
ESTEVE CDMO (Esteve Química) shines as a global leader focused on third-party CDMO services, particularly in high-quality small-molecule APIs and pharmaceutical intermediates. The company provides cutting-edge technologies, including Spray Drying and the manufacturing of high-potency APIs (HPAPIs).
"The United States represents a crucial market for ESTEVE. This acquisition strengthens our commitment to improving people's lives by expanding our CDMO capabilities and enhancing our integrated service offerings," commented Staffan Schüberg, CEO of ESTEVE.
Scott Aladeen, President and CEO of Regis Technologies, added, "Joining ESTEVE is exciting as it aligns with our shared values. As a family-owned organization with over 90 years of experience, ESTEVE is committed to delivering long-term value to its clients while prioritizing its people."
Two Focusing Businesses of ESTEVE
ESTEVE operates under two main business segments: contract development and manufacturing for active pharmaceutical ingredients and a pharmaceutical business that focuses on creating specialized medicines. Their production presence spans various countries, including Spain, Mexico, China, and now the United States.
The pharmaceutical segment of ESTEVE delivers specialized medicines through affiliations in Germany, France, Italy, Portugal, the UK, and the USA. This comprehensive reach allows ESTEVE to address significant medical needs across multiple therapeutic areas.
About ESTEVE
Established in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical firm with a resolute mission of enhancing the quality of life for individuals worldwide. The organization boasts a significant international footprint, with pharmaceutical affiliates in numerous countries, including Spain, Portugal, Italy, Germany, France, the UK, and the USA.
Focusing on specialized treatments for unmet medical needs, ESTEVE offers thorough Contract Manufacturing and Development services through its state-of-the-art facilities worldwide—a commitment substantiated by its dedication to core values of people, transparency, and accountability.
About Regis Technologies
Regis Technologies, Inc. partners with biotechnology and pharmaceutical companies to streamline the journey from drug candidate to market. They provide comprehensive services from process and analytical development to stability services and cGMP API manufacturing. Their commitment to quality and excellence is evident through their facilities being routinely inspected by global regulatory authorities, including the FDA.
Founded by Dr. Louis Glunz III in 1956 in Chicago, Regis Technologies remains privately owned, emphasizing the importance of customer-centered value and innovation in every aspect of its operations.
Frequently Asked Questions
What is the significance of ESTEVE acquiring Regis Technologies?
The acquisition strengthens ESTEVE's position in the U.S. market, enhances their CDMO capabilities, and expands their manufacturing services for small-molecule APIs.
How long has Regis Technologies been operational?
Regis Technologies has been in operation since 1956, providing extensive services in API manufacturing and development.
Who is the CEO of ESTEVE?
Staffan Schüberg is the CEO of ESTEVE and plays a crucial role in steering the company's strategic direction.
What kind of services does ESTEVE CDMO provide?
ESTEVE CDMO specializes in manufacturing small-molecule active pharmaceutical ingredients, offering a variety of process research, development, and analytical services.
Where are ESTEVE's production plants located?
ESTEVE has production facilities in Spain, Mexico, China, and now the United States, covering a global operational scope.
